If You Invested in Incannex Healthcare Ltd (IXHL)
Custom Calculation
Choose your own date and amount for IXHL$1,000 Investment Over Time
IXHL vs S&P 500Year-by-Year Returns
IXHL annual performance| Year | Start Price | End Price | Annual Return | Cumulative |
|---|---|---|---|---|
| 2022 | $446.40 | $84.00 | -81.2% | -81.2% |
| 2023 | $91.35 | $139.20 | +52.4% | -68.8% |
| 2024 | $132.00 | $63.60 | -51.8% | -85.8% |
| 2025 | $60.45 | $10.74 | -82.2% | -97.6% |
| 2026 | $11.70 | $3.96 | -66.2% | -99.1% |
About Incannex Healthcare Ltd
Pharmaceutical Preparations · NASDAQ
Incannex Healthcare Inc. develops clinical-stage biopharmaceutical programs based on combination therapies and regulated botanical wellness medicine. The company’s common stock trades on Nasdaq under the symbol IXHL. Its business is centered on research and development programs for high-impact medical conditions, with company disclosures emphasizing investigational therapies for obstructive sleep apnea and generalized anxiety disorder.
The company’s lead disclosed program is IHL-42X, an investigational oral fixed-dose combination of dronabinol and acetazolamide designed for the treatment of obstructive sleep apnea. Incannex has described IHL-42X as a therapy intended to target underlying mechanisms of obstructive sleep apnea through the combined activity of its two active pharmaceutical ingredients. The program has been reported with Phase 2 clinical results, and the U.S. Food and Drug Administration has granted Fast Track Designation for IHL-42X.
Incannex also develops PSX-001, an oral fixed-dose synthetic botanical research compound formulation in development for generalized anxiety disorder. The company has reported completed Phase 2 clinical work for PSX-001 and positions the program within its broader development focus on novel therapies for serious mental-health conditions.
Incannex manages its business as one reportable and operating segment focused on research and development involving regulated botanical wellness medicine and therapies. Earlier company materials also describe an Australian license to import, export and distribute medicinal cannabis products, as well as a launched line of cannabinoid products. The company’s current public communications emphasize clinical development, regulatory interaction, capital structure, Nasdaq listing status and financing activities related to its investigational pipeline.
Corporate filings identify Incannex Healthcare Inc. as an emerging growth company and list its common stock as registered on The Nasdaq Stock Market LLC. The company has also disclosed capital-structure actions, including a completed 1-for-30 reverse stock split of its common stock and Nasdaq minimum bid price compliance matters. Its principal office is listed in Melbourne, Australia.
Similar Stocks
See how related companies performed
Frequently Asked Questions
Incannex Healthcare Ltd investment returns
How much would $1,000 invested in Incannex Healthcare Ltd be worth today?
If you invested $1,000 in Incannex Healthcare Ltd (IXHL) 10 years ago on 2022-03-02, your investment would be worth $9 today, representing a -99.1% total return, growing at a compounded rate of -67.5% per year (CAGR).
Has Incannex Healthcare Ltd outperformed the S&P 500?
Over the past 10 years, IXHL returned -99.1% compared to +260.7% for the S&P 500, underperforming the benchmark by 359.8 percentage points.
What is Incannex Healthcare Ltd's average annual return?
The compound annual growth rate (CAGR) of IXHL over the past 10 years is -67.5%, growing at a compounded rate each year. Individual years vary significantly — IXHL's best recent year was 2023 (+52.4%) and worst was 2025 (-82.2%).
Your Privacy is Protected
This calculator sends the symbol, date, and amount you enter to our server so we can fetch historical market data and render the result. We do not save those entries as a portfolio or account, but standard web server logs may still record the page request.
For informational and educational purposes only — not investment advice.
